Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline

Jazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.